Reported results
- Collaboration revenue was $0.9 million for the third quarter of 2026, compared to $1.6 million for the same period in 2025.
- Research & Development (R&D) expenses were $32.4 million for the third quarter of 2026, compared to $38.4 million for the same period in 2025.
- General & Administrative (G&A) expenses were $10.2 million for the third quarter of 2026, compared to $10.3 million for the same period in 2025.
- Net loss was $39.7 million for the third quarter of 2026, compared to $44.1 million for the same period in 2025.
- Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, compared to $295.7 million as of December 31, 2025.
Guidance
- The Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
